Search | Clinical Trials Finder

Conditions: Hemophilia A
Interventions: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 6 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Hemophilia A
Interventions: Not listed
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2040
U.S. locations: 13
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 10 more

Conditions: Hemophilia A
Interventions: SPK-8011; Genetic
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 27
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 23 more

Conditions: Hemophilia A
Interventions: Not listed
Lead sponsor: Victor J Marder, M.D.; Other
Eligibility: 2 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Hemophilia A
Interventions: Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2033
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
Interventions: Valoctocogene roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hemophilia A
Interventions: valoctocogene roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 15
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 12 more

Conditions: Hemophilia A
Interventions: BAY2599023 (DTX201); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Little Rock, Arkansas • Ann Arbor, Michigan • Madison, Wisconsin

Conditions: Hemophilia A, Prophylaxis of Bleeding
Interventions: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).; Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more

Conditions: Hemophilia A
Interventions: Valoctocogene Roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hemophilia
Interventions: rFVIII; Drug
Lead sponsor: Craig Seaman; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Von Willebrand Disease (VWD)
Interventions: Vonicog Alfa, ADVATE; Biological
Lead sponsor: Takeda; Industry
Eligibility: Up to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 11
States / cities: Birmingham, Alabama • Peoria, Illinois • Indianapolis, Indiana + 8 more

Conditions: Haemophilia A
Interventions: Recombinant Factor VIII (Kovaltry, BAY81-8973); Biological
Lead sponsor: Bayer; Industry
Eligibility: 0 Years to 12 Years · Male only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 4
States / cities: New Orleans, Louisiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more

Conditions: Hemophilia A
Interventions: Nuwiq; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Von Willebrand Disease, Blood Coagulation Disorders, Blood Platelet Disorders, Hematologic Disease
Interventions: Blood coagulation Factor VIII and vWF, human; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hemophilia A, Hemophilia B
Interventions: ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant]); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more

Conditions: Hemophilia
Interventions: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013; Biological
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: Not listed
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 27
States / cities: San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more

Conditions: Hemophilia A
Interventions: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 50 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 28
States / cities: Tucson, Arizona • Little Rock, Arkansas • Orange, California + 23 more

Conditions: Hemophilia A
Interventions: ReFacto, Advante; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Iowa City, Iowa + 1 more

Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions: coagulation factor VIIa [recombinant]-jncw; Drug
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: 12 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 10
States / cities: Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 7 more

Conditions: Von Willebrand Disease (VWD)
Interventions: rVWF, rFVIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 0 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 8
States / cities: Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 5 more

Conditions: Hemophilia A
Interventions: Moroctocog alfa(AF-CC), Blood draw for laboratory testing; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Detroit, Michigan + 2 more

Conditions: Von Willebrand Disease
Interventions: Vonicog alfa, Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 16
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more

Search by objective public record fields.

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

Study of a Gene Therapy Treatment for Hemophilia A

Personalized Prediction of Tolerance and Immunogenicity in Hemophilia

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

Prophylaxis Regimen for Hemophilia A Patients

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg

Weight-based Dosing in Hemophilia A

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

BAY81-8973 Pediatric Safety and Efficacy Trial

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

ATHN 2: Factor Switching Study

Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Study Evaluating The Safety Of Xyntha In Usual Care Settings

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)